NCT02179489View on ClinicalTrials.gov

Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis

NACompletedINTERVENTIONAL
Enrollment

271

Participants

Timeline

Start Date

November 1, 2014

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions
Malignant Neoplasm of Large Intestine TNM Staging Primary Tumor (T) T4Peritoneal Carcinomatosis
Interventions
PROCEDURE

Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC

HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.

Trial Locations (9)

110042

Liaoning Cancer Hospital, Shenyang

200032

Zhongshan Hospital Fudan University, Shanghai

310003

The First Affiliated Hospital of College of Medicine Zhejiang University, Hangzhou

310009

Second Affiliated Hospitalof Zhejiang University School of Medicine, Hangzhou

310016

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

312000

People's Hospital of Shaoxing, Shaoxing

315400

Yuyao People's Hospital, Yuyao

321000

Jinhua People's Hospital, Jinhua

350001

Union Hospital Fujian Medical University, Fuzhou

All Listed Sponsors
lead

Zhejiang University

OTHER

NCT02179489 - Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis | Biotech Hunter | Biotech Hunter